Exact Sciences EXAS

HealthcareMarket cap $8B3 connections

Exact Sciences makes Cologuard - a non-invasive colon cancer screening test using a stool sample that detects DNA shed by cancer cells. 6M+ patients have used it instead of colonoscopies. Its Oncotype DX test predicts breast cancer recurrence, guiding chemotherapy decisions for 200,000+ patients annually.

Open Exact Sciences's Company Hub Simulate a merger Supply chain See it on the map

Suppliers 1

Companies that sell to Exact Sciences

AmazonConsumer & Retail · $2.7TCologuard kits shipped via Amazon logistics

Customers 1

Companies Exact Sciences sells to

CVS HealthHealthcare · $114BExact Sciences tests ordered through CVS MinuteClinic

Partners 1

Strategic partnerships, joint products and alliances

UnitedHealthHealthcare · $338BUnitedHealth covers Cologuard colon cancer screening

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Exact Sciences's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=EXAS" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Exact Sciences on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.